Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/bitter-us-pill-on-drug-patents-jayanta-roy-chowdhury-24177/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/bitter-us-pill-on-drug-patents-jayanta-roy-chowdhury-24177/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/bitter-us-pill-on-drug-patents-jayanta-roy-chowdhury-24177/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/bitter-us-pill-on-drug-patents-jayanta-roy-chowdhury-24177/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0ba02097a2-trace').style.display = (document.getElementById('cakeErr67f0ba02097a2-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f0ba02097a2-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0ba02097a2-code').style.display = (document.getElementById('cakeErr67f0ba02097a2-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0ba02097a2-context').style.display = (document.getElementById('cakeErr67f0ba02097a2-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f0ba02097a2-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f0ba02097a2-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 24005,
		&#039;title&#039; =&gt; &#039;Bitter US pill on drug patents -Jayanta Roy Chowdhury&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India&#039;s trade and practices on intellectual property rights (IPR).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi&#039;s move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &amp;quot;We won&#039;t be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India, along with China, Russia, Argentina and Egypt, is already on the US government&#039;s priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In its submission, the Chamber of Commerce said, &amp;quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&amp;quot; it said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US has been unhappy over what it considers India&#039;s &amp;quot;misuse&amp;quot; of intellectual property laws to build its domestic industry at the expense of US innovators.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In December last year, Bayer&#039;s chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &amp;quot;for Indians. We developed it for western patients who can afford it&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &amp;quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India&#039;s international obligations.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India&#039;s aviation safety rating to Category 2 last month. 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 9 February, 2014, http://www.telegraphindia.com/1140209/jsp/business/story_17916638.jsp#.UvcQBfsd4rZ&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;bitter-us-pill-on-drug-patents-jayanta-roy-chowdhury-24177&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 24177,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 24005,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Bitter US pill on drug patents -Jayanta Roy Chowdhury&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;patents,generic medicine,generic drugs,Health,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph



New Delhi: The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.


In a recommendation to the United...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India&#039;s trade and practices on intellectual property rights (IPR).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi&#039;s move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &amp;quot;We won&#039;t be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India, along with China, Russia, Argentina and Egypt, is already on the US government&#039;s priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In its submission, the Chamber of Commerce said, &amp;quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&amp;quot; it said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US has been unhappy over what it considers India&#039;s &amp;quot;misuse&amp;quot; of intellectual property laws to build its domestic industry at the expense of US innovators.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In December last year, Bayer&#039;s chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &amp;quot;for Indians. We developed it for western patients who can afford it&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &amp;quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India&#039;s international obligations.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India&#039;s aviation safety rating to Category 2 last month. &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 24005,
	&#039;title&#039; =&gt; &#039;Bitter US pill on drug patents -Jayanta Roy Chowdhury&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India&#039;s trade and practices on intellectual property rights (IPR).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi&#039;s move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &amp;quot;We won&#039;t be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India, along with China, Russia, Argentina and Egypt, is already on the US government&#039;s priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In its submission, the Chamber of Commerce said, &amp;quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&amp;quot; it said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US has been unhappy over what it considers India&#039;s &amp;quot;misuse&amp;quot; of intellectual property laws to build its domestic industry at the expense of US innovators.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In December last year, Bayer&#039;s chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &amp;quot;for Indians. We developed it for western patients who can afford it&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &amp;quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India&#039;s international obligations.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India&#039;s aviation safety rating to Category 2 last month. 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 9 February, 2014, http://www.telegraphindia.com/1140209/jsp/business/story_17916638.jsp#.UvcQBfsd4rZ&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;bitter-us-pill-on-drug-patents-jayanta-roy-chowdhury-24177&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 24177,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 24005
$metaTitle = &#039;LATEST NEWS UPDATES | Bitter US pill on drug patents -Jayanta Roy Chowdhury&#039;
$metaKeywords = &#039;patents,generic medicine,generic drugs,Health,medicines&#039;
$metaDesc = &#039;
-The Telegraph



New Delhi: The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.


In a recommendation to the United...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India&#039;s trade and practices on intellectual property rights (IPR).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi&#039;s move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &amp;quot;We won&#039;t be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India, along with China, Russia, Argentina and Egypt, is already on the US government&#039;s priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In its submission, the Chamber of Commerce said, &amp;quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&amp;quot; it said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US has been unhappy over what it considers India&#039;s &amp;quot;misuse&amp;quot; of intellectual property laws to build its domestic industry at the expense of US innovators.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In December last year, Bayer&#039;s chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &amp;quot;for Indians. We developed it for western patients who can afford it&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &amp;quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India&#039;s international obligations.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India&#039;s aviation safety rating to Category 2 last month. &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/bitter-us-pill-on-drug-patents-jayanta-roy-chowdhury-24177.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Bitter US pill on drug patents -Jayanta Roy Chowdhury | Im4change.org</title>
    <meta name="description" content="
-The Telegraph



New Delhi: The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.


In a recommendation to the United..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Bitter US pill on drug patents -Jayanta Roy Chowdhury</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph</div><p align="justify"><br /><em>New Delhi: </em>The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.</p><p align="justify">In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.</p><p align="justify">The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India's trade and practices on intellectual property rights (IPR).</p><p align="justify">The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi's move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.</p><p align="justify">Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &quot;We won't be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&quot;</p><p align="justify">Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.</p><p align="justify">India, along with China, Russia, Argentina and Egypt, is already on the US government's priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.</p><p align="justify">The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.</p><p align="justify">In its submission, the Chamber of Commerce said, &quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&quot;</p><p align="justify">&quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&quot; it said.</p><p align="justify">Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.</p><p align="justify">The US has been unhappy over what it considers India's &quot;misuse&quot; of intellectual property laws to build its domestic industry at the expense of US innovators.</p><p align="justify">In December last year, Bayer's chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &quot;for Indians. We developed it for western patients who can afford it&quot;.</p><p align="justify">US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.</p><p align="justify">This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India's international obligations.&quot;</p><p align="justify">The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India's aviation safety rating to Category 2 last month. </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0ba02097a2-trace').style.display = (document.getElementById('cakeErr67f0ba02097a2-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f0ba02097a2-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0ba02097a2-code').style.display = (document.getElementById('cakeErr67f0ba02097a2-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0ba02097a2-context').style.display = (document.getElementById('cakeErr67f0ba02097a2-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f0ba02097a2-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f0ba02097a2-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 24005,
		&#039;title&#039; =&gt; &#039;Bitter US pill on drug patents -Jayanta Roy Chowdhury&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India&#039;s trade and practices on intellectual property rights (IPR).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi&#039;s move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &amp;quot;We won&#039;t be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India, along with China, Russia, Argentina and Egypt, is already on the US government&#039;s priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In its submission, the Chamber of Commerce said, &amp;quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&amp;quot; it said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US has been unhappy over what it considers India&#039;s &amp;quot;misuse&amp;quot; of intellectual property laws to build its domestic industry at the expense of US innovators.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In December last year, Bayer&#039;s chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &amp;quot;for Indians. We developed it for western patients who can afford it&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &amp;quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India&#039;s international obligations.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India&#039;s aviation safety rating to Category 2 last month. 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 9 February, 2014, http://www.telegraphindia.com/1140209/jsp/business/story_17916638.jsp#.UvcQBfsd4rZ&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;bitter-us-pill-on-drug-patents-jayanta-roy-chowdhury-24177&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 24177,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 24005,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Bitter US pill on drug patents -Jayanta Roy Chowdhury&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;patents,generic medicine,generic drugs,Health,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph



New Delhi: The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.


In a recommendation to the United...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India&#039;s trade and practices on intellectual property rights (IPR).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi&#039;s move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &amp;quot;We won&#039;t be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India, along with China, Russia, Argentina and Egypt, is already on the US government&#039;s priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In its submission, the Chamber of Commerce said, &amp;quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&amp;quot; it said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US has been unhappy over what it considers India&#039;s &amp;quot;misuse&amp;quot; of intellectual property laws to build its domestic industry at the expense of US innovators.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In December last year, Bayer&#039;s chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &amp;quot;for Indians. We developed it for western patients who can afford it&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &amp;quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India&#039;s international obligations.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India&#039;s aviation safety rating to Category 2 last month. &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 24005,
	&#039;title&#039; =&gt; &#039;Bitter US pill on drug patents -Jayanta Roy Chowdhury&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India&#039;s trade and practices on intellectual property rights (IPR).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi&#039;s move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &amp;quot;We won&#039;t be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India, along with China, Russia, Argentina and Egypt, is already on the US government&#039;s priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In its submission, the Chamber of Commerce said, &amp;quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&amp;quot; it said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US has been unhappy over what it considers India&#039;s &amp;quot;misuse&amp;quot; of intellectual property laws to build its domestic industry at the expense of US innovators.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In December last year, Bayer&#039;s chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &amp;quot;for Indians. We developed it for western patients who can afford it&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &amp;quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India&#039;s international obligations.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India&#039;s aviation safety rating to Category 2 last month. 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 9 February, 2014, http://www.telegraphindia.com/1140209/jsp/business/story_17916638.jsp#.UvcQBfsd4rZ&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;bitter-us-pill-on-drug-patents-jayanta-roy-chowdhury-24177&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 24177,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 24005
$metaTitle = &#039;LATEST NEWS UPDATES | Bitter US pill on drug patents -Jayanta Roy Chowdhury&#039;
$metaKeywords = &#039;patents,generic medicine,generic drugs,Health,medicines&#039;
$metaDesc = &#039;
-The Telegraph



New Delhi: The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.


In a recommendation to the United...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India&#039;s trade and practices on intellectual property rights (IPR).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi&#039;s move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &amp;quot;We won&#039;t be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India, along with China, Russia, Argentina and Egypt, is already on the US government&#039;s priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In its submission, the Chamber of Commerce said, &amp;quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&amp;quot; it said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US has been unhappy over what it considers India&#039;s &amp;quot;misuse&amp;quot; of intellectual property laws to build its domestic industry at the expense of US innovators.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In December last year, Bayer&#039;s chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &amp;quot;for Indians. We developed it for western patients who can afford it&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &amp;quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India&#039;s international obligations.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India&#039;s aviation safety rating to Category 2 last month. &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/bitter-us-pill-on-drug-patents-jayanta-roy-chowdhury-24177.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Bitter US pill on drug patents -Jayanta Roy Chowdhury | Im4change.org</title>
    <meta name="description" content="
-The Telegraph



New Delhi: The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.


In a recommendation to the United..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Bitter US pill on drug patents -Jayanta Roy Chowdhury</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph</div><p align="justify"><br /><em>New Delhi: </em>The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.</p><p align="justify">In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.</p><p align="justify">The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India's trade and practices on intellectual property rights (IPR).</p><p align="justify">The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi's move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.</p><p align="justify">Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &quot;We won't be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&quot;</p><p align="justify">Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.</p><p align="justify">India, along with China, Russia, Argentina and Egypt, is already on the US government's priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.</p><p align="justify">The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.</p><p align="justify">In its submission, the Chamber of Commerce said, &quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&quot;</p><p align="justify">&quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&quot; it said.</p><p align="justify">Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.</p><p align="justify">The US has been unhappy over what it considers India's &quot;misuse&quot; of intellectual property laws to build its domestic industry at the expense of US innovators.</p><p align="justify">In December last year, Bayer's chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &quot;for Indians. We developed it for western patients who can afford it&quot;.</p><p align="justify">US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.</p><p align="justify">This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India's international obligations.&quot;</p><p align="justify">The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India's aviation safety rating to Category 2 last month. </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0ba02097a2-trace').style.display = (document.getElementById('cakeErr67f0ba02097a2-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f0ba02097a2-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0ba02097a2-code').style.display = (document.getElementById('cakeErr67f0ba02097a2-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0ba02097a2-context').style.display = (document.getElementById('cakeErr67f0ba02097a2-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f0ba02097a2-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f0ba02097a2-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 24005,
		&#039;title&#039; =&gt; &#039;Bitter US pill on drug patents -Jayanta Roy Chowdhury&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India&#039;s trade and practices on intellectual property rights (IPR).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi&#039;s move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &amp;quot;We won&#039;t be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India, along with China, Russia, Argentina and Egypt, is already on the US government&#039;s priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In its submission, the Chamber of Commerce said, &amp;quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&amp;quot; it said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US has been unhappy over what it considers India&#039;s &amp;quot;misuse&amp;quot; of intellectual property laws to build its domestic industry at the expense of US innovators.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In December last year, Bayer&#039;s chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &amp;quot;for Indians. We developed it for western patients who can afford it&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &amp;quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India&#039;s international obligations.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India&#039;s aviation safety rating to Category 2 last month. 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 9 February, 2014, http://www.telegraphindia.com/1140209/jsp/business/story_17916638.jsp#.UvcQBfsd4rZ&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;bitter-us-pill-on-drug-patents-jayanta-roy-chowdhury-24177&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 24177,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 24005,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Bitter US pill on drug patents -Jayanta Roy Chowdhury&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;patents,generic medicine,generic drugs,Health,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph



New Delhi: The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.


In a recommendation to the United...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India&#039;s trade and practices on intellectual property rights (IPR).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi&#039;s move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &amp;quot;We won&#039;t be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India, along with China, Russia, Argentina and Egypt, is already on the US government&#039;s priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In its submission, the Chamber of Commerce said, &amp;quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&amp;quot; it said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US has been unhappy over what it considers India&#039;s &amp;quot;misuse&amp;quot; of intellectual property laws to build its domestic industry at the expense of US innovators.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In December last year, Bayer&#039;s chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &amp;quot;for Indians. We developed it for western patients who can afford it&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &amp;quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India&#039;s international obligations.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India&#039;s aviation safety rating to Category 2 last month. &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 24005,
	&#039;title&#039; =&gt; &#039;Bitter US pill on drug patents -Jayanta Roy Chowdhury&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India&#039;s trade and practices on intellectual property rights (IPR).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi&#039;s move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &amp;quot;We won&#039;t be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India, along with China, Russia, Argentina and Egypt, is already on the US government&#039;s priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In its submission, the Chamber of Commerce said, &amp;quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&amp;quot; it said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US has been unhappy over what it considers India&#039;s &amp;quot;misuse&amp;quot; of intellectual property laws to build its domestic industry at the expense of US innovators.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In December last year, Bayer&#039;s chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &amp;quot;for Indians. We developed it for western patients who can afford it&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &amp;quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India&#039;s international obligations.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India&#039;s aviation safety rating to Category 2 last month. 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 9 February, 2014, http://www.telegraphindia.com/1140209/jsp/business/story_17916638.jsp#.UvcQBfsd4rZ&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;bitter-us-pill-on-drug-patents-jayanta-roy-chowdhury-24177&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 24177,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 24005
$metaTitle = &#039;LATEST NEWS UPDATES | Bitter US pill on drug patents -Jayanta Roy Chowdhury&#039;
$metaKeywords = &#039;patents,generic medicine,generic drugs,Health,medicines&#039;
$metaDesc = &#039;
-The Telegraph



New Delhi: The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.


In a recommendation to the United...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India&#039;s trade and practices on intellectual property rights (IPR).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi&#039;s move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &amp;quot;We won&#039;t be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India, along with China, Russia, Argentina and Egypt, is already on the US government&#039;s priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In its submission, the Chamber of Commerce said, &amp;quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&amp;quot; it said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US has been unhappy over what it considers India&#039;s &amp;quot;misuse&amp;quot; of intellectual property laws to build its domestic industry at the expense of US innovators.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In December last year, Bayer&#039;s chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &amp;quot;for Indians. We developed it for western patients who can afford it&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &amp;quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India&#039;s international obligations.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India&#039;s aviation safety rating to Category 2 last month. &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/bitter-us-pill-on-drug-patents-jayanta-roy-chowdhury-24177.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Bitter US pill on drug patents -Jayanta Roy Chowdhury | Im4change.org</title>
    <meta name="description" content="
-The Telegraph



New Delhi: The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.


In a recommendation to the United..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Bitter US pill on drug patents -Jayanta Roy Chowdhury</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph</div><p align="justify"><br /><em>New Delhi: </em>The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.</p><p align="justify">In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.</p><p align="justify">The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India's trade and practices on intellectual property rights (IPR).</p><p align="justify">The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi's move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.</p><p align="justify">Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &quot;We won't be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&quot;</p><p align="justify">Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.</p><p align="justify">India, along with China, Russia, Argentina and Egypt, is already on the US government's priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.</p><p align="justify">The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.</p><p align="justify">In its submission, the Chamber of Commerce said, &quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&quot;</p><p align="justify">&quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&quot; it said.</p><p align="justify">Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.</p><p align="justify">The US has been unhappy over what it considers India's &quot;misuse&quot; of intellectual property laws to build its domestic industry at the expense of US innovators.</p><p align="justify">In December last year, Bayer's chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &quot;for Indians. We developed it for western patients who can afford it&quot;.</p><p align="justify">US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.</p><p align="justify">This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India's international obligations.&quot;</p><p align="justify">The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India's aviation safety rating to Category 2 last month. </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 24005,
		'title' => 'Bitter US pill on drug patents -Jayanta Roy Chowdhury',
		'subheading' => '',
		'description' => '<div align="justify">
-The Telegraph
</div>
<p align="justify">
<br />
<em>New Delhi: </em>The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.
</p>
<p align="justify">
In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.
</p>
<p align="justify">
The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India's trade and practices on intellectual property rights (IPR).
</p>
<p align="justify">
The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi's move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.
</p>
<p align="justify">
Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &quot;We won't be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&quot;
</p>
<p align="justify">
Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.
</p>
<p align="justify">
India, along with China, Russia, Argentina and Egypt, is already on the US government's priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.
</p>
<p align="justify">
The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.
</p>
<p align="justify">
In its submission, the Chamber of Commerce said, &quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&quot;
</p>
<p align="justify">
&quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&quot; it said.
</p>
<p align="justify">
Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.
</p>
<p align="justify">
The US has been unhappy over what it considers India's &quot;misuse&quot; of intellectual property laws to build its domestic industry at the expense of US innovators.
</p>
<p align="justify">
In December last year, Bayer's chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &quot;for Indians. We developed it for western patients who can afford it&quot;.
</p>
<p align="justify">
US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.
</p>
<p align="justify">
This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India's international obligations.&quot;
</p>
<p align="justify">
The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India's aviation safety rating to Category 2 last month. 
</p>',
		'credit_writer' => 'The Telegraph, 9 February, 2014, http://www.telegraphindia.com/1140209/jsp/business/story_17916638.jsp#.UvcQBfsd4rZ',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'bitter-us-pill-on-drug-patents-jayanta-roy-chowdhury-24177',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 24177,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 24005,
	'metaTitle' => 'LATEST NEWS UPDATES | Bitter US pill on drug patents -Jayanta Roy Chowdhury',
	'metaKeywords' => 'patents,generic medicine,generic drugs,Health,medicines',
	'metaDesc' => '
-The Telegraph



New Delhi: The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.


In a recommendation to the United...',
	'disp' => '<div align="justify">-The Telegraph</div><p align="justify"><br /><em>New Delhi: </em>The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.</p><p align="justify">In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.</p><p align="justify">The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India's trade and practices on intellectual property rights (IPR).</p><p align="justify">The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi's move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.</p><p align="justify">Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &quot;We won't be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&quot;</p><p align="justify">Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.</p><p align="justify">India, along with China, Russia, Argentina and Egypt, is already on the US government's priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.</p><p align="justify">The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.</p><p align="justify">In its submission, the Chamber of Commerce said, &quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&quot;</p><p align="justify">&quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&quot; it said.</p><p align="justify">Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.</p><p align="justify">The US has been unhappy over what it considers India's &quot;misuse&quot; of intellectual property laws to build its domestic industry at the expense of US innovators.</p><p align="justify">In December last year, Bayer's chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &quot;for Indians. We developed it for western patients who can afford it&quot;.</p><p align="justify">US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.</p><p align="justify">This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India's international obligations.&quot;</p><p align="justify">The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India's aviation safety rating to Category 2 last month. </p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 24005,
	'title' => 'Bitter US pill on drug patents -Jayanta Roy Chowdhury',
	'subheading' => '',
	'description' => '<div align="justify">
-The Telegraph
</div>
<p align="justify">
<br />
<em>New Delhi: </em>The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.
</p>
<p align="justify">
In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.
</p>
<p align="justify">
The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India's trade and practices on intellectual property rights (IPR).
</p>
<p align="justify">
The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi's move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.
</p>
<p align="justify">
Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &quot;We won't be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&quot;
</p>
<p align="justify">
Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.
</p>
<p align="justify">
India, along with China, Russia, Argentina and Egypt, is already on the US government's priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.
</p>
<p align="justify">
The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.
</p>
<p align="justify">
In its submission, the Chamber of Commerce said, &quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&quot;
</p>
<p align="justify">
&quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&quot; it said.
</p>
<p align="justify">
Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.
</p>
<p align="justify">
The US has been unhappy over what it considers India's &quot;misuse&quot; of intellectual property laws to build its domestic industry at the expense of US innovators.
</p>
<p align="justify">
In December last year, Bayer's chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &quot;for Indians. We developed it for western patients who can afford it&quot;.
</p>
<p align="justify">
US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.
</p>
<p align="justify">
This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India's international obligations.&quot;
</p>
<p align="justify">
The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India's aviation safety rating to Category 2 last month. 
</p>',
	'credit_writer' => 'The Telegraph, 9 February, 2014, http://www.telegraphindia.com/1140209/jsp/business/story_17916638.jsp#.UvcQBfsd4rZ',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'bitter-us-pill-on-drug-patents-jayanta-roy-chowdhury-24177',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 24177,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 24005
$metaTitle = 'LATEST NEWS UPDATES | Bitter US pill on drug patents -Jayanta Roy Chowdhury'
$metaKeywords = 'patents,generic medicine,generic drugs,Health,medicines'
$metaDesc = '
-The Telegraph



New Delhi: The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.


In a recommendation to the United...'
$disp = '<div align="justify">-The Telegraph</div><p align="justify"><br /><em>New Delhi: </em>The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection.</p><p align="justify">In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine.</p><p align="justify">The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India's trade and practices on intellectual property rights (IPR).</p><p align="justify">The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi's move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV.</p><p align="justify">Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, &quot;We won't be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures.&quot;</p><p align="justify">Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications.</p><p align="justify">India, along with China, Russia, Argentina and Egypt, is already on the US government's priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action.</p><p align="justify">The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR.</p><p align="justify">In its submission, the Chamber of Commerce said, &quot;We highlight India as a country with particular challenges with respect to intellectual property protections.&quot;</p><p align="justify">&quot;Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country,&quot; it said.</p><p align="justify">Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion.</p><p align="justify">The US has been unhappy over what it considers India's &quot;misuse&quot; of intellectual property laws to build its domestic industry at the expense of US innovators.</p><p align="justify">In December last year, Bayer's chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine &quot;for Indians. We developed it for western patients who can afford it&quot;.</p><p align="justify">US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent.</p><p align="justify">This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, &quot;The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India's international obligations.&quot;</p><p align="justify">The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India's aviation safety rating to Category 2 last month. </p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Bitter US pill on drug patents -Jayanta Roy Chowdhury

-The Telegraph New Delhi: The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection. In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only country on the list is Ukraine. The tough stance, also backed by the US Pharmaceutical Research and Manufacturers of America, would trigger a stringent monitoring of India's trade and practices on intellectual property rights (IPR). The Indian pharma industry as well as government officials believe the real cause of the US ire is New Delhi's move to review patented drugs by MNCs to allow the manufacture of low-cost, generic versions of drugs for the treatment of life-threatening diseases such as cancer, diabetes, hepatitis and HIV. Sunil Pophale, managing director of Reelabs India and former co-founder of Fem Care Pharma, said, "We won't be impacted by their measures. Indians have now become generic drug manufacturers in the US. We know how to handle these pressures." Reelabs works on stem-cell therapy for neuro-degenerative and bone and cartilage disorders and holds 15 patents for stem-cell applications. India, along with China, Russia, Argentina and Egypt, is already on the US government's priority watch list, which ensures that its IPR practices are closely monitored by the USTR for possible retaliatory action. The downgrade would mean a stricter watch and more threats for tit-for-tat action. The recommendations, which were due by Friday, were for a document known as a Special 301 Report prepared annually by the office of the USTR. In its submission, the Chamber of Commerce said, "We highlight India as a country with particular challenges with respect to intellectual property protections." "Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country," it said. Analysts point out that the Indian drug market is expected to be worth $25-30 billion by 2017, making it the 11th largest in the world, according to IMS Health. India exports drugs worth $20 billion. The US has been unhappy over what it considers India's "misuse" of intellectual property laws to build its domestic industry at the expense of US innovators. In December last year, Bayer's chief executive officer Marijn Dekkers had said his firm had not developed a cancer medicine "for Indians. We developed it for western patients who can afford it". US drug giant Pfizer last year suffered a setback with the Supreme Court letting rival Indian drug makers sell generic versions of its kidney cancer drug Sutent. This prompted Senator Max Baucus to write a letter to the US Secretary of State John Kerry in June last year, saying, "The misuse of patent law to hand US intellectual property to Indian companies is inconsistent with India's international obligations." The recommendation by the US chamber comes close on the heels of the US Federal Aviation Administration downgrading India's aviation safety rating to Category 2 last month.